Compare LGHL & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGHL | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.9K | 972.3K |
| IPO Year | 2020 | 2021 |
| Metric | LGHL | VRAX |
|---|---|---|
| Price | $0.68 | $0.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 408.6K | ★ 565.2K |
| Earning Date | 04-30-2024 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.10 |
| 52 Week High | $9.54 | $13.19 |
| Indicator | LGHL | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 29.11 | 16.47 |
| Support Level | $0.58 | $0.15 |
| Resistance Level | $1.13 | $0.53 |
| Average True Range (ATR) | 0.34 | 0.18 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 3.97 | 3.16 |
Lion Group Holding Ltd provides an investor-focused trading platform that offers various products and services. The company's current business lines include total return swap (TRS) trading business, contracts for difference (CFD) trading services, and Over-The-Counter (OTC) stock options trading business. It offers these services through its all-in-one Lion Brokers Pro app and a variety of other apps available on iOS, Android, PC, and Mac platforms. The company's clients are mostly well-educated and affluent Chinese investors residing both inside and outside the PRC (excluding the United States). Its operating segments are: OTC Stock option trading, which generates maximum revenue, CFD trading, TRS trading, and Other. Geographically, the company derives maximum revenue from Hong Kong.
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.